> 数据图表咨询大家港股医药1H25业绩：创新药表现靓丽，头部CXO上调全年指引2025-11-6港股医药1H25业绩：创新药表现靓丽，头部CXO上调全年指引收入（百万元）归母净利润（百万元）PEPS21A22A23A24A1H2521A22A23A24A1H2525E26E27E25E26E27E整体YoY化药YoY创新药YoY医疗服务YoYCXOYoY医药流通YoY医疗器械YoY1,510,378 1,690,682 1,846,910 1,895,828974,042(2,207)12,85041,54679,75957,54319.419.218.35.94.93.711.9%9.2%2.6%2.4%223.3%92.0%54.9%201,743214,790216,256225,463117,00746,47030,91531,82135,33223,50717.515.013.93.33.02.76.5%0.7%4.3%1.3%-33.5%2.9%11.0%7.4%24,86830,41053,47169,64142,290(57,716)(47,627)(29,786)(21,535)(1,113)---20.213.011.422.3%75.8%30.2%32.9%-17.5%-37.5%-27.7%-89.6%43,12753,26261,54762,73030,8532,2612,5993,6232,9091,47214.811.59.91.41.51.523.5%15.6%1.9%-0.8%15.0%39.4%-19.7%-34.0%59,13094,29698,85897,20652,70712,97519,28120,00038,52313,19825.223.118.15.85.84.659.5%4.8%-1.7%14.5%48.6%3.7%92.6%86.4%931,9231,012,670 1,103,135 1,118,963560,15016,07618,08316,82215,10510,0507.26.96.40.10.10.18.7%8.9%1.4%-0.6%12.5%-7.0%-10.2%7.5%42,05248,59550,10752,18726,738(6,786)(4,120)(2,448)7651,71918.218.718.15.94.83.715.6%3.1%4.2%2.9%-39.3%-40.6%-131.3%56.8%资料来源：Wind，申万宏源研究。注：数据包括191家港股医药公司www.swsresearch.com 证券研究报告14申万宏源健康医疗
